Altered Expression of Transforming Growth Factor Beta-S During Urethral and Bulbourethral Gland Tumor Progression in Transgenic Mice Carrying the Androgen-Responsive C3(1) 5' Flanking Region Fused to Sv40 Large T Antigen

We demonstrate that targeted expression of SV40 large T antigen (TAg) to the urethral (periurethral) and bulbourethral gland epithelium leads to adenocarcinoma formation in these tissues after 7 months of age, which are extremely rare sites for spontaneous tumor formation in humans, The development of proliferative lesions in the urethral gland predictably follows a temporal course of progression with approximately one third of male animals developing urethral tumors by 1 year of age, Tumor progression in these organs correlates to the level of TAg and p53 expression. Immunoprecipitation confirmed that SV40 TAg protein was bound to p53 and Rb p110 in vivo. Expression of transforming growth factor beta (TGF beta s) was evaluated during tumor progression of urethral gland carcinomas, Elevations of intracellular and extracellular TGF beta 1 and extracellular TGF beta 3 were found in preneoplastic and neoplastic lesions, suggesting that increased TGF beta s may augment tumor growth, c-Met expression showed a tendency for increased expression in the urethral gland carcinomas, We speculate that the directed expression of SV40 TAg by the hormone responsive C3(1) gene and subsequent tumor formation in these organs is influenced by androgens, since these tissues and carcinomas express androgen receptor (AR) and arise only in male transgenic mice, Several cell lines established from the urethral carcinomas were also shown to express AR, but are not androgen dependent in culture. To our knowledge, this is the first transgenic animal model for urethral and bulbourethral carcinomas, This transgenic mouse model and the cell lines derived from it may pro,ide a unique opportunity for dissecting molecular mechanisms involved in the tumorigenesis of these organs which otherwise rarely develop cancer. [References: 51]

See More